UOC
RLAY icon

UBS O'Connor’s Relay Therapeutics RLAY Stock Holding History

UBS O'Connor’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-110,000
Closed -$12.5K – 554
2024
Q3 		$12.5K Buy
+110,000
New +$822K ﹤0.01% 458
2023
Q4 		– Sell
-80,000
Closed -$40K – 584
2023
Q3 		$40K Buy
+80,000
New +$860K ﹤0.01% 495

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS O'Connor's RLAY Position: Q3 2025 in Review

UBS O'Connor sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 127,036 shares — an estimated $440K sold.

UBS O'Connor first reported a position in RLAY in Q4 2022 and held it in 10 quarters. The position peaked at $1.47M in Q4 2023. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • UBS O'Connor reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 127,036 Relay Therapeutics shares in Q3 2025, an estimated $440K.
  • UBS O'Connor first reported a position in Relay Therapeutics in Q4 2022 and held it in 10 quarters.
  • UBS O'Connor's Relay Therapeutics position peaked at $1.47M in Q4 2023.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.